{"pmid":32313880,"pmcid":"PMC7166201","title":"PAK1-blockers: Potential Therapeutics against COVID-19.","text":["PAK1-blockers: Potential Therapeutics against COVID-19.","PAK1 (RAC/CDC42-activated kinase 1) is the major \"pathogenic\" kinase whose abnormal activation causes a wide variety of diseases/disorders including cancers, inflammation, malaria and pandemic viral infection including influenza, HIV and COVID-19. Since Louis Pateur who developed a vaccine against rabies in 1885, in general a series of \"specific\" vaccines have been used for treatment of viral infection, mainly because antibiotics in general are ineffective for treatment of viral infection. However, it takes 12-18months till the effective vaccine becomes available. Until then ventilator (O2 supplier) would be the most common tool for saving the life of COVID-19 patients. Thus, as alternative potentially more direct \"broad-spectrum\" COVID-19 therapeutics, several natural and synthetic PAK1-blockers such as propolis, melatonin, ciclesonide, hydroxy chloroquine (HQ), ivermection, and ketorolac, which are readily available in the market, are introduced here.","Med Drug Discov","Maruta, Hiroshi","He, Hong","32313880"],"abstract":["PAK1 (RAC/CDC42-activated kinase 1) is the major \"pathogenic\" kinase whose abnormal activation causes a wide variety of diseases/disorders including cancers, inflammation, malaria and pandemic viral infection including influenza, HIV and COVID-19. Since Louis Pateur who developed a vaccine against rabies in 1885, in general a series of \"specific\" vaccines have been used for treatment of viral infection, mainly because antibiotics in general are ineffective for treatment of viral infection. However, it takes 12-18months till the effective vaccine becomes available. Until then ventilator (O2 supplier) would be the most common tool for saving the life of COVID-19 patients. Thus, as alternative potentially more direct \"broad-spectrum\" COVID-19 therapeutics, several natural and synthetic PAK1-blockers such as propolis, melatonin, ciclesonide, hydroxy chloroquine (HQ), ivermection, and ketorolac, which are readily available in the market, are introduced here."],"journal":"Med Drug Discov","authors":["Maruta, Hiroshi","He, Hong"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32313880","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.medidd.2020.100039","keywords":["covid-19","pak1","cancer","pathogenic kinase","viral infection"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["propolis"],"e_drugs":["Ketorolac","Hydroxychloroquine","ciclesonide","Melatonin"],"_version_":1664714520153554944,"score":8.518259,"similar":[{"pmid":32271454,"title":"Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19.","text":["Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19.","Beginning in December 2019, coronavirus disease 2019 (COVID-19), due to 2019-nCoV infection, emerged in Wuhan and spread rapidly throughout China and even worldwide. Employing combined therapy of modern medicine and traditional Chinese medicine has been proposed, in which Ma Xing Shi Gan Decoction (MXSGD) was recommended as a basic prescription and applied widely in the clinical treatment of COVID-19. We investigated the underlying mechanism of MXSGD in treating COVID-19 utilizing the approaches of integrating network pharmacology. A total of 97 active ingredients of MXSGD were screened out, and 169 targets were predicted. The protein-protein interaction network exhibited hub targets of MXSGD, such as Heat shock protein 90, RAC-alpha serine/threonine-protein kinase, Transcription factor AP-1, Mitogen-activated protein kinase 1, Cellular tumor antigen p53, Vascular endothelial growth factor A, and Tumour necrosis factor. Gene Ontology functional enrichment analysis demonstrated that the biological processes altered within the body after taking MXSGD were closely related to the regulation of such processes as the acute inflammatory response, chemokine production, vascular permeability, response to oxygen radicals, oxidative stress-induced apoptosis, T cell differentiation involved in the immune response, immunoglobulin secretion, and extracellular matrix disassembly. KEGG enrichment analysis indicated that the targets of MXSGD were significantly enriched in inflammation-related pathways, immunomodulation-related pathways, and viral infection-related pathways. The therapeutic mechanisms of MXSGD on COVID-19 may primarily involve the following effects: reducing inflammation, suppressing cytokine storm, protecting the pulmonary alveolar-capillary barrier, alleviating pulmonary edema, regulating the immune response, and decreasing fever.","Eur Rev Med Pharmacol Sci","Wang, Y-X","Ma, J-R","Wang, S-Q","Zeng, Y-Q","Zhou, C-Y","Ru, Y-H","Zhang, L","Lu, Z-G","Wu, M-H","Li, H","32271454"],"abstract":["Beginning in December 2019, coronavirus disease 2019 (COVID-19), due to 2019-nCoV infection, emerged in Wuhan and spread rapidly throughout China and even worldwide. Employing combined therapy of modern medicine and traditional Chinese medicine has been proposed, in which Ma Xing Shi Gan Decoction (MXSGD) was recommended as a basic prescription and applied widely in the clinical treatment of COVID-19. We investigated the underlying mechanism of MXSGD in treating COVID-19 utilizing the approaches of integrating network pharmacology. A total of 97 active ingredients of MXSGD were screened out, and 169 targets were predicted. The protein-protein interaction network exhibited hub targets of MXSGD, such as Heat shock protein 90, RAC-alpha serine/threonine-protein kinase, Transcription factor AP-1, Mitogen-activated protein kinase 1, Cellular tumor antigen p53, Vascular endothelial growth factor A, and Tumour necrosis factor. Gene Ontology functional enrichment analysis demonstrated that the biological processes altered within the body after taking MXSGD were closely related to the regulation of such processes as the acute inflammatory response, chemokine production, vascular permeability, response to oxygen radicals, oxidative stress-induced apoptosis, T cell differentiation involved in the immune response, immunoglobulin secretion, and extracellular matrix disassembly. KEGG enrichment analysis indicated that the targets of MXSGD were significantly enriched in inflammation-related pathways, immunomodulation-related pathways, and viral infection-related pathways. The therapeutic mechanisms of MXSGD on COVID-19 may primarily involve the following effects: reducing inflammation, suppressing cytokine storm, protecting the pulmonary alveolar-capillary barrier, alleviating pulmonary edema, regulating the immune response, and decreasing fever."],"journal":"Eur Rev Med Pharmacol Sci","authors":["Wang, Y-X","Ma, J-R","Wang, S-Q","Zeng, Y-Q","Zhou, C-Y","Ru, Y-H","Zhang, L","Lu, Z-G","Wu, M-H","Li, H"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32271454","week":"202015|Apr 06 - Apr 12","doi":"10.26355/eurrev_202003_20704","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["Wuhan","China","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664637315719364610,"score":216.49466},{"pmid":32209231,"pmcid":"PMC7094376","title":"Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus.","text":["Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus.","This paper concerns study of the genome of the Wuhan Seafood Market isolate believed to represent the causative agent of the disease COVID-19. This is to find a short section or sections of viral protein sequence suitable for preliminary design proposal for a peptide synthetic vaccine and a peptidomimetic therapeutic, and to explore some design possibilities. The project was originally directed towards a use case for the Q-UEL language and its implementation in a knowledge management and automated inference system for medicine called the BioIngine, but focus here remains mostly on the virus itself. However, using Q-UEL systems to access relevant and emerging literature, and to interact with standard publically available bioinformatics tools on the Internet, did help quickly identify sequences of amino acids that are well conserved across many coronaviruses including 2019-nCoV. KRSFIEDLLFNKV was found to be particularly well conserved in this study and corresponds to the region around one of the known cleavage sites of the SARS virus that are believed to be required for virus activation for cell entry. This sequence motif and surrounding variations formed the basis for proposing a specific synthetic vaccine epitope and peptidomimetic agent. The work can, nonetheless, be described in traditional bioinformatics terms, and readily reproduced by others, albeit with the caveat that new data and research into 2019-nCoV is emerging and evolving at an explosive pace. Preliminary studies using molecular modeling and docking, and in that context the potential value of certain known herbal extracts, are also described.","Comput Biol Med","Robson, B","32209231"],"abstract":["This paper concerns study of the genome of the Wuhan Seafood Market isolate believed to represent the causative agent of the disease COVID-19. This is to find a short section or sections of viral protein sequence suitable for preliminary design proposal for a peptide synthetic vaccine and a peptidomimetic therapeutic, and to explore some design possibilities. The project was originally directed towards a use case for the Q-UEL language and its implementation in a knowledge management and automated inference system for medicine called the BioIngine, but focus here remains mostly on the virus itself. However, using Q-UEL systems to access relevant and emerging literature, and to interact with standard publically available bioinformatics tools on the Internet, did help quickly identify sequences of amino acids that are well conserved across many coronaviruses including 2019-nCoV. KRSFIEDLLFNKV was found to be particularly well conserved in this study and corresponds to the region around one of the known cleavage sites of the SARS virus that are believed to be required for virus activation for cell entry. This sequence motif and surrounding variations formed the basis for proposing a specific synthetic vaccine epitope and peptidomimetic agent. The work can, nonetheless, be described in traditional bioinformatics terms, and readily reproduced by others, albeit with the caveat that new data and research into 2019-nCoV is emerging and evolving at an explosive pace. Preliminary studies using molecular modeling and docking, and in that context the potential value of certain known herbal extracts, are also described."],"journal":"Comput Biol Med","authors":["Robson, B"],"date":"2020-03-27T11:00:00Z","year":2020,"_id":"32209231","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.compbiomed.2020.103670","keywords":["2019-ncov coronavirus","automatic browser","bioinformatics","peptidomimetic","q-uel language","retroinverso","synthetic vaccine","wuhan seafood market coronavirus"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["Q-UEL"],"_version_":1664638933365948416,"score":203.97122},{"pmid":32322401,"pmcid":"PMC7171518","title":"Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics).","text":["Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics).","The coronavirus disease (COVID-19) is highly pathogenic viral infection caused by SARS-CoV-2. Currently, COVID-19 has caused global health concern. It is assumed that COVID-19 has zoonotic origin based on the large number of infected people who were exposed to the wet market in Wuhan City, China. The phylogenetic analysis has revealed that SARS-CoV-2 has significant sequence similarity with severe acute respiratory syndrome-like (SARS-like) bat viruses, thus bats could be primary possible reservoir. The intermediate host and there subsequent transfer is not known yet, although human to human transfer is widely confirmed. The transmission of COVID-19 infection from one person to another resulted in the isolation of patients who were subsequently given a variety of treatments. To monitor the current outbreak, robust steps have been taken around the globe to reduce the transmission of COVID-19 infection particularly banning international and domestic flights, inducting lockdowns in vulnerable areas, social distancing etc. No clinically approved antiviral drug or vaccine against COVID-19 is reported yet. However, in clinical trials, few broad-spectrum antiviral drugs were evaluated against COVID-19 infection which resulted in clinical recovery. In this article emergence and pathogenicity of COVID-19 infection along with potential therapeutic strategies are analyzed to combat the COVID-19 pandemic.","New Microbes New Infect","Hamid, Saima","Mir, Mohammad Yaseen","Rohela, Gulab Khan","32322401"],"abstract":["The coronavirus disease (COVID-19) is highly pathogenic viral infection caused by SARS-CoV-2. Currently, COVID-19 has caused global health concern. It is assumed that COVID-19 has zoonotic origin based on the large number of infected people who were exposed to the wet market in Wuhan City, China. The phylogenetic analysis has revealed that SARS-CoV-2 has significant sequence similarity with severe acute respiratory syndrome-like (SARS-like) bat viruses, thus bats could be primary possible reservoir. The intermediate host and there subsequent transfer is not known yet, although human to human transfer is widely confirmed. The transmission of COVID-19 infection from one person to another resulted in the isolation of patients who were subsequently given a variety of treatments. To monitor the current outbreak, robust steps have been taken around the globe to reduce the transmission of COVID-19 infection particularly banning international and domestic flights, inducting lockdowns in vulnerable areas, social distancing etc. No clinically approved antiviral drug or vaccine against COVID-19 is reported yet. However, in clinical trials, few broad-spectrum antiviral drugs were evaluated against COVID-19 infection which resulted in clinical recovery. In this article emergence and pathogenicity of COVID-19 infection along with potential therapeutic strategies are analyzed to combat the COVID-19 pandemic."],"journal":"New Microbes New Infect","authors":["Hamid, Saima","Mir, Mohammad Yaseen","Rohela, Gulab Khan"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32322401","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.nmni.2020.100679","keywords":["covid-19","pathogenesis","phylogenetic analysis","therapeutic strategies","transmission"],"source":"PubMed","topics":["Prevention","Mechanism","Treatment"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664895932628467712,"score":197.2978},{"pmid":32217117,"pmcid":"PMC7102583","title":"COVID-19: Melatonin as a potential adjuvant treatment.","text":["COVID-19: Melatonin as a potential adjuvant treatment.","This article summarizes the likely benefits of melatonin in the attenuation of COVID-19 based on its putative pathogenesis. The recent outbreak of COVID-19 has become a pandemic with tens of thousands of infected patients. Based on clinical features, pathology, the pathogenesis of acute respiratory disorder induced by either highly homogenous coronaviruses or other pathogens, the evidence suggests that excessive inflammation, oxidation, and an exaggerated immune response very likely contribute to COVID-19 pathology. This leads to a cytokine storm and subsequent progression to acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and often death. Melatonin, a well-known anti-inflammatory and anti-oxidative molecule, is protective against ALI/ARDS caused by viral and other pathogens. Melatonin is effective in critical care patients by reducing vessel permeability, anxiety, sedation use, and improving sleeping quality, which might also be beneficial for better clinical outcomes for COVID-19 patients. Notably, melatonin has a high safety profile. There is significant data showing that melatonin limits virus-related diseases and would also likely be beneficial in COVID-19 patients. Additional experiments and clinical studies are required to confirm this speculation.","Life Sci","Zhang, Rui","Wang, Xuebin","Ni, Leng","Di, Xiao","Ma, Baitao","Niu, Shuai","Liu, Changwei","Reiter, Russel J","32217117"],"abstract":["This article summarizes the likely benefits of melatonin in the attenuation of COVID-19 based on its putative pathogenesis. The recent outbreak of COVID-19 has become a pandemic with tens of thousands of infected patients. Based on clinical features, pathology, the pathogenesis of acute respiratory disorder induced by either highly homogenous coronaviruses or other pathogens, the evidence suggests that excessive inflammation, oxidation, and an exaggerated immune response very likely contribute to COVID-19 pathology. This leads to a cytokine storm and subsequent progression to acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and often death. Melatonin, a well-known anti-inflammatory and anti-oxidative molecule, is protective against ALI/ARDS caused by viral and other pathogens. Melatonin is effective in critical care patients by reducing vessel permeability, anxiety, sedation use, and improving sleeping quality, which might also be beneficial for better clinical outcomes for COVID-19 patients. Notably, melatonin has a high safety profile. There is significant data showing that melatonin limits virus-related diseases and would also likely be beneficial in COVID-19 patients. Additional experiments and clinical studies are required to confirm this speculation."],"journal":"Life Sci","authors":["Zhang, Rui","Wang, Xuebin","Ni, Leng","Di, Xiao","Ma, Baitao","Niu, Shuai","Liu, Changwei","Reiter, Russel J"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32217117","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.lfs.2020.117583","keywords":["covid-19","cytokines","immunomodulation","melatonin","oxidation-reduction","sars-cov-2"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Melatonin"],"_version_":1664638743024238592,"score":188.47316},{"pmid":32334502,"title":"The mechanistic target of rapamycin (mTOR): Novel Considerations as an Antiviral Treatment and Possibilities for COVID-19.","text":["The mechanistic target of rapamycin (mTOR): Novel Considerations as an Antiviral Treatment and Possibilities for COVID-19.","As a rapidly developing etiology of a global disease, the -coronavirus family virion, SARS-CoV-2, has quickly evolved as a pandemic leading to coronavirus disease 2019 (COVID-19) and has been declared by the World Health Organization as a Public Health Emergency of International Concern. To date, no definitive treatment or vaccine application exists for COVID-19. Although new investigations seek to repurpose existing antiviral treatments for COVID-19, innovative treatment strategies not normally considered to have antiviral capabilities may be critical as well to address this global concern. One such avenue that may prove to be exceeding fruitful and offer exciting potential as new antiviral therapy involves the mechanistic target of rapamycin (mTOR) and its associated pathways of mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), and AMP activated protein kinase (AMPK). Recent work has shown that mTOR pathways in conjunction with AMPK may offer valuable targets to control cell injury, oxidative stress, and the onset of hyperinflammation, a significant disability tied to COVID-19. Furthermore, pathways that can activate mTOR may be necessary for antihepatitis C activity, reduction of influenza A virus replication, and vital for type-1 interferon responses with influenza vaccination. Yet, important considerations for the development of safe and effective antiviral therapy with mTOR pathways exist. Under some conditions, mTOR can act as a double edge sword and participate in virion replication and virion release from cells. Future work with mTOR as a potential antiviral target is highly warranted and with greater understanding of this novel pathway, new Maiese, CNR 17,3, mTOR and Antivirals, treatments against several viral infections may successfully emerge including therapy directed for SARS-CoV-2 and COVID-19.","Curr Neurovasc Res","Maiese, Kenneth","32334502"],"abstract":["As a rapidly developing etiology of a global disease, the -coronavirus family virion, SARS-CoV-2, has quickly evolved as a pandemic leading to coronavirus disease 2019 (COVID-19) and has been declared by the World Health Organization as a Public Health Emergency of International Concern. To date, no definitive treatment or vaccine application exists for COVID-19. Although new investigations seek to repurpose existing antiviral treatments for COVID-19, innovative treatment strategies not normally considered to have antiviral capabilities may be critical as well to address this global concern. One such avenue that may prove to be exceeding fruitful and offer exciting potential as new antiviral therapy involves the mechanistic target of rapamycin (mTOR) and its associated pathways of mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), and AMP activated protein kinase (AMPK). Recent work has shown that mTOR pathways in conjunction with AMPK may offer valuable targets to control cell injury, oxidative stress, and the onset of hyperinflammation, a significant disability tied to COVID-19. Furthermore, pathways that can activate mTOR may be necessary for antihepatitis C activity, reduction of influenza A virus replication, and vital for type-1 interferon responses with influenza vaccination. Yet, important considerations for the development of safe and effective antiviral therapy with mTOR pathways exist. Under some conditions, mTOR can act as a double edge sword and participate in virion replication and virion release from cells. Future work with mTOR as a potential antiviral target is highly warranted and with greater understanding of this novel pathway, new Maiese, CNR 17,3, mTOR and Antivirals, treatments against several viral infections may successfully emerge including therapy directed for SARS-CoV-2 and COVID-19."],"journal":"Curr Neurovasc Res","authors":["Maiese, Kenneth"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32334502","week":"202018|Apr 27 - May 03","doi":"10.2174/1567202617666200425205122","keywords":["amp activated protein kinase (ampk)","akt","covid-19","sars-cov-2","angiotensin converting enzyme 2","apoptosis","autophagy","coronaviruses","cytokines","diabetes mellitus","inflammation","influenza","interferons","interleukins","mtor complex 1 (mtorc1)","mtor complex 2 (mtorc2)","macrophage inflammatory protein 1-alpha (mip-1alpha)","mechanistic target of rapamycin (mtor)","metformin","monocyte chemoattractant protein 1 (mcp-1)","oxidative stress","tumor necrosis factor-alpha","virion"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["Maiese"],"_version_":1665172301950222336,"score":184.668}]}